{"schema_version":"secwatch.filing_event.v1","accession":"0001585364-26-000044","form_type":"8-K","ticker":"PRGO","cik":"0001585364","company_name":"PERRIGO Co plc","filed_at":"2026-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.523817+00:00","generated_at":"2026-05-14T22:43:28.440223+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Perrigo Q1 net sales $969M (-7.2%), adj EPS $0.43 (-28%); reaffirms FY 2026 outlook","bullets":["All In net sales $969M, down 7.2% YoY; reported diluted EPS $(2.81) due to $330.8M goodwill impairment.","Core adjusted EPS $0.40, down 20% YoY; Core organic net sales -11.0% reflecting lower seasonal cough/cold and retailer destocking.","After quarter end, completed Dermacosmetics sale for upfront cash of €306M; proceeds to support debt reduction.","Self Care segment net sales down 11.5%, operating income down 39.3% due to lower volumes and prior-year manufacturing headwinds.","Full-year 2026 outlook reaffirmed; expects second-half improvement from lapping headwinds and OEP."],"urls":{"canonical":"https://secwatch.observer/filing/0001585364-26-000044","json":"https://secwatch.observer/filing/0001585364-26-000044.json","markdown":"https://secwatch.observer/filing/0001585364-26-000044.md","text":"https://secwatch.observer/filing/0001585364-26-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585364/000158536426000044/0001585364-26-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585364/000158536426000044/prgo-20260506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:43:28.440223+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ab15059628af53863f18bc069e7252afca41be98","claim":"PERRIGO Co plc reported the first quarter ended March 28, 2026 results: revenue $969 million, EPS $(2.81). Guidance reaffirmed.","evidence_excerpt":"of Women’s Health products. Core organic net sales comprised net pricing of 0.2% and volume/mix of -11.0%. • All In reported net sales declined 7.2% year over year to $969 million. The decrease was driven by the same factors impacting Core net sales, partially offset by Infant Formula net sales growth. Gross Margin • Reported gross margin was 33.6%, a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585364/000158536426000044/0001585364-26-000044-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 28, 2026"},{"label":"Revenue","value":"$969 million"},{"label":"EPS","value":"$(2.81)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}